Market Intelligence, Clinical Progress, and High-Purity Reagents for Hippo Pathway-Targeted Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for YAP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | YAP1 Recombinant Protein (Full-Length & TEAD-Binding Domain, WT & S127A Mutant) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Theoretical MW confirmed. Includes phospho-deficient S127A mutant for constitutive activation studies. |
View YAP1 Products |
| Gene Delivery | YAP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and reporter assays. |
View YAP1 Products |
| Benchmark Ab | Anti-YAP1 Recombinant Antibody (High-Affinity Clone) High-specificity positive control for WB, IF, IHC, and nuclear translocation validation. |
View YAP1 Products |
| Validator | YAP1 siRNA Set Sequence-optimized for knockdown verification and target engagement confirmation. |
View YAP1 Products |
| Related Target A | TEAD1 Recombinant Protein (DNA-Binding Domain & Full-Length) Direct YAP1 binding partner; essential for YAP-TEAD interaction assays. |
View TEAD1 Products |
| Related Target B | TAZ (WWTR1) Recombinant Protein Paralog of YAP1; critical for selectivity counter-screening and compensatory resistance bypass analysis. |
View TAZ Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| YAP1-TEAD PPI Disruption (AlphaScreen/SPR/TR-FRET) | High-purity full-length YAP1 & isolated TBD (aa 230–265) proteins, including WT and S127A mutant; endotoxin <1EU/µg preserves cell viability. |
| Constitutive Activation Mutant Controls | Phospho-deficient mutants (S127A, 5SA) and phospho-mimetic variants expressed in HEK293; theoretical MW confirmed by MS for mechanistic studies. |
| Paralog Selectivity (YAP1 vs TAZ) | Human WWTR1 (TAZ) protein available with >95% purity for cross-reactivity ELISA/SPR panels. |
| Stable Reporter Cell Line Generation | High-titer YAP1 ORF Lentivirus (Promise-ORF) for flow cytometry or luciferase integration; ideal for degradation kinetics and reporter assays. |
| Target Engagement & Knockdown Specificity | Sequence-verified siRNA set and validated recombinant antibodies for orthogonal specificity checks. |
| Subcellular Localization Assays | High-purity antigens suitable for immunogen use in antibody generation for nuclear/cytoplasmic detection. |
Live YAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for YAP1 therapeutics is intensifying, with major players shifting focus from indirect Hippo pathway modulation to direct disruption of the YAP1-TEAD transcriptional complex. As first-generation TEAD palmitoylation inhibitors (e.g., VT3989, IK-930) enter Phase I/II clinical evaluation, the next wave of R&D is targeting paralog-selective inhibition (YAP1 vs TAZ), synthetic lethal combinations with MAPK pathway inhibitors (e.g., KRAS G12C, EGFR inhibitors), and intracellular delivery modalities (PROTACs, stapled peptides) capable of engaging the transcriptional co-activator in the nuclear compartment. YAP1 activation is a primary escape mechanism for cells resisting targeted therapies, making combination regimens a dominant future trend. High-fidelity in vitro assays using recombinant full-length YAP1 and phospho-status mutants are now critical differentiators for claiming mechanistic specificity in crowded oncology pipelines.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI & Palmitoylation Inhibitors) | Vivace Therapeutics, Ikena Oncology | NF2-mutant Mesothelioma, Solid Tumors (HCC, NSCLC) | YAP-TEAD Disruption Assay (Need high-purity recombinant proteins and mutant controls) |
| Peptide / Macrocycle Inhibitors | Rainbow Therapeutics, Academic Labs | NF2-deficient Tumors, Mesothelioma | Cell Permeability & PPI SPR/AlphaScreen (Need high-purity TBD and TEAD proteins) |
| PROTAC / Degrader | Emerging Biotech | Refractory NSCLC, Liver Cancer | Ternary Complex Formation & Degradation Kinetics (Need full-length YAP1 with native conformation and lentivirus stable cell lines) |
| siRNA / Synthetic Lethal / RNAi | Various Preclinical / Academic | KRAS-mutant Cancers, Advanced Solid Tumors | Knockdown Efficacy Validation & Isoform Selectivity (Need YAP1/TAZ siRNA set and sequence-verified antibodies) |
| Upstream Kinase Activators | Various | Immunotherapy Combinations | LATS1-mediated Phosphorylation Assay (Need active LATS1 + YAP1 substrate) |